Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 2 Completed 13 enrolled Novo Nordisk A/S

RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate pharmacokinetics, pharmacodynamics and safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.

Timeline

Start: 1997-04
Primary completion: 1998-11
Completion: 1998-11

Publications

Results McSorley PT, Bell PM, Jacobsen LV, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther. 2002 Apr;24(4):530-9. doi: 10.1016/s0149-2918(02)85129-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	biphasic human insulin	Protein / enzyme biologic	—	Subcutaneous
Subject	biphasic insulin aspart	Protein / enzyme biologic	—	Subcutaneous

Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Summary

Timeline

Publications

Drugs

Indications